Lilly Puts Zepbound and Foundayo Directly on Hims & Hers Platform
LLY sits 58% above its 52-week low of $850.51 on elevated volume (1.9× avg).
Summary
Lilly struck a deal letting Hims & Hers sell Zepbound and Foundayo directly on its telehealth platform, removing the step where patients had to leave the site for LillyDirect. That friction was costing conversions, and the arrangement puts Lilly on equal footing with Novo Nordisk, which has sold Wegovy and Ozempic through Hims & Hers since March. Hims & Hers agreed to stop selling compounded versions or knockoffs of Lilly's obesity drugs, a meaningful concession given the prior litigation Novo brought over compounded copycats. Self-pay pricing matches LillyDirect at $149 a month for the Foundayo pill and $299 for Zepbound, with 40% to 45% of Zepbound sales already running through self-pay channels. The deal is modest next to Lilly's $1.2 trillion valuation and $24.4B quarterly revenue, but it widens a direct-to-consumer channel that is growing in importance as employers weigh dropping weight-loss coverage.
At the time of this announcement, LLY was trading at $1,346.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3T. The 52-week trading range was $850.51 to $1,453.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.